Logo Lanfrica
  • Home
  • Atlas
  • Insights
  • Docs
  • Sign in

© 2026 Lanfrica. All rights reserved. All copyrights of the resources shown on the Lanfrica website belong to the original copyright holders, unless explicitly stated otherwise.

Dysregulated gene expression predicts tumor aggressiveness in African-American prostate cancer patients

Domain:

healthcare

Record type:

paper
Creator:
HamPeiAndSha
Publisher:
Spr
Host:
Abstract Molecular mechanisms underlying the health disparity of prostate cancer (PCa) have not been fully determined. In this study, we applied bioinformatic approach to identify and validate dysregulated genes associated with tumor aggressiveness in African American (AA) compared to Caucasian American (CA) men with PCa. We retrieved and analyzed microarray data from 619 PCa patients, 412 AA and 207 CA, and we validated these genes in tumor tissues and cell lines by Real-Time PCR, Western blot, immunocytochemistry (ICC) and immunohistochemistry (IHC) analyses. We identified 362 differentially expressed genes in AA men and involved in regulating signaling pathways associated with tumor aggressiveness. In PCa tissues and cells, NKX3.1, APPL2, TPD52, LTC4S, ALDH1A3 and AMD1 transcripts were significantly upregulated (p < 0.05) compared to normal cells. IHC confirmed the overexpression of TPD52 (p = 0.0098) and LTC4S (p < 0.0005) in AA compared to CA men. ICC and Western blot analyses additionally corroborated this observation in PCa cells. These findings suggest that dysregulation of transcripts in PCa may drive the disparity of PCa outcomes and provide new insights into development of new therapeutic agents against aggressive tumors. More studies are warranted to investigate the clinical significance of these dysregulated genes in promoting the oncogenic pathways in AA men.

Visit

doi.org

Licenses

https://creativecommons.org/licenses/by/4.0https://creativecommons.org/licenses/by/4.0

Similar

Data from RGS12 Is a Novel Tumor-Suppressor Gene in African American Prostate Cancer That Represses AKT and MNX1 ExpressionDifferential Gene Expression between African American and European American Colorectal Cancer PatientsTumor Immunobiological Differences in Prostate Cancer between African-American and European-American MenPerformance of the Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) Tumor Biomarker for Identifying Recurrent Disease in African American PatientsEvaluating p53 nuclear expression and prostate cancer progression in a predominantly African American cohort.In Silico Identification of Prostate Cancer Biomarkers from Gene Expression Datasets

Data from RGS12 Is a Novel Tumor-Suppressor Gene in African American Prostate Cancer That Represses AKT and MNX1 Expression

Abstract

African American (AA) men exhibit a relatively high incidence and mortal

Differential Gene Expression between African American and European American Colorectal Cancer Patients

The incidence and mortality of colorectal cancer (CRC) is higher in African Americans (AAs)

Tumor Immunobiological Differences in Prostate Cancer between African-American and European-American Men

Abstract The incidence and mortality rates of prostate cancer are significantly

Performance of the Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) Tumor Biomarker for Identifying Recurrent Disease in African American Patients

Abstract Evaluation of prostate cancer prognosis after surgery is increasingly r

Evaluating p53 nuclear expression and prostate cancer progression in a predominantly African American cohort.

217 Background: Increased utilization of next-generation sequencing has revealed evidence of earl

In Silico Identification of Prostate Cancer Biomarkers from Gene Expression Datasets

Abstract